Puma Biotech (PBYI) options in a fast market on announces posting of FDA advisory committee documents
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) call put ratio is 1.2 calls to 1 put on announcing that the U.S. Food and Drug Administration posted briefing documents on its website in preparation for the May 24 Oncologic Drugs Advisory Committee meeting scheduled to review PB272, or neratinib, for the extended adjuvant treatment of HER2-positive early stage breast cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ): FDA Advisers Unanimously Vote that carvykti Benefits Outweighing Risks as Earlier Treatment for a Type of Blood Cancer
- Active options: META MSFT MARA SMCI TLRY BA SOUN RIVN PYPL HOOD
- Ametek (AME) option IV low as share price near upper end of range
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!